China's unique position in discovery and preclinical research (original) (raw)
Related papers
Cancer drug development in China: recent advances and future challenges
Drug discovery today, 2014
Over the past 10 years, the Chinese Government, academic organizations, and biopharmaceutical companies have tried to transition the nation from a consumer of generic drugs into a developer of innovative therapies. Here, we present a timeline of recent innovative cancer drug development, with a particular focus on four case studies that have reshaped perceptions of what can be done in China. We present metrics comparing China with other countries alongside analysis of what national authorities are doing to close the gap in areas where China still lags behind the West.
Tracking the current rise of Chinese pharmaceutical bionanotechnology
Journal of biomedical discovery and …, 2009
ABSTRACTBackground: The Context and Purpose of the StudyOver the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China’s scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measure the impact of Chinese policy on nanotechnology research production.Results, the main findingsOur text mining-based methods provide results that counter existing claims about Chinese nanotechnology research quality. Due in large part to its strategic innovation policy, China’s output of nanotechnology publications is on pace to surpass US production in or around 2012.A closer look at Chinese nanotechnology research literature reveals a large increase in research activity in China’s biopharmananotechnology research since the implementation in January, 2006 of China’s Medium & Long Term Scientific and Technological Development Plan Guidelines for the period 2006-2020 (“MLP”). Since the implementation of the MLP, China has enjoyed a great deal of success producing bionano research findings while attracting a great deal of foreign investment from pharmaceutical corporations setting up advanced drug discovery operations. Given the combination of current scientific production growth as well as economic growth, a relatively low scientific capacity, and the ability of its policy to enhance such trends, China is in some sense already the new world leader in nanotechnology. Further, the Chinese national innovation system may be the new standard by which other national S&T policies should be measured.
Challenges and Opportunities With Oncology Drug Development in China
Clinical pharmacology and therapeutics, 2018
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.
2015
Background: This article sets up the initial discussion of the evolution of biopharmaceutical innovation in China through the perspective of sectoral innovation system (SIS). Methods: Two data sources including archival documentary data and field interviews were used in this study. Archival documentary data was collected from China Food and Drug Administration (CFDA) and Chinese National Knowledge Infrastructure (CNKI). In addition, industrial practitioners and leading researchers in academia were interviewed. Results: Biopharmaceutical in China was established through international knowledge transfer. The firms played more active role in commercializing biopharmaceutical in China though universities and research institutes were starting to interact with local firms and make contribution to biopharmaceutical industrialization. The transition of the Chinese government’s policies continuously shapes the evolution of biopharmaceutical sector. Policies have been dramatic changes before and after 1980s to encourage developing biopharmaceutical as a competitive industry for China. Conclusion: A SIS for biopharmaceutical has been shaped in China. However, currently biopharmaceutical is still a small sector in China, and for the further growth of the industry more synthetic policies should be implemented. Not only the policy supports towards the research and innovation of biopharmaceuticals in the early stage of development should be attended, but also commercialization of biopharmaceutical products in the later stage of sales.
Chemistry in China—A bibliometric view
2009
ABSTRACT Based on bibliometric analysis, this paper explores China's publication activity in chemistry. China develops fast in chemical research and has taken a leading position in publishing journal papers. International collaboration plays a role in the Chinese chemical community, but this role varies among subfields.
US NCI-China Collaborative Studies
Journal of the National Cancer Institute , 2017
Since 2007, the US National Cancer Institute (NCI) Office of Cancer Complementary and Alternative Medicine (OCCAM), together with the Cancer Institute of the China Academy of Chinese Medical Sciences (CICACMS), institutes at China Academy of Sciences and Chinese Academy of Medical Sciences, have engaged in collaborations on Chinese medicine (CM) and cancer research. Through these collaborations, CM drugs and compounds have been studied at NCI labs. This paper summarizes the discoveries and progress on these research projects, exploring the aspects of cancer prevention, botanical drug mechanisms of action and component analysis/quality control (QC), and anticancer activity screening. These and other related projects have been presented in various jointly convened workshops and have provided the backdrop for establishing a new organization, the International Consortium for CM and Cancer, to promote international collaborations in this field.
2015
Despite the increasing availability of chemicals, the number of New Drug Approvals (NDA) from the Food and Drug Administration (FDA) remains unchanged. The number of chemical structures available online via web-based open source applications will reach the symbolic 1 billion in the 10 next years. However, for no apparent reasons, the number of NDA accepted yearly has not changed in the past 25 years. One of the emerging paradigms of Big Pharma is that the more we know about molecular mechanisms and cell signaling pathways, the less we understand how to use this knowledge to make New Chemical Entities (NCE). Moreover, the annual number of pharmaceutical patents collected in the OCSE database has virtually not increased. Unexpectedly, the number of patents originating in the USA is decreasing significantly, while Asia is doing very well. The comparison between the number of NCEs and the American investment in Research and Development (R&D) in the last 35 years shows that to obtain a n...